Exporter

You can select particular sections to be included in the output file.
EN
FR

Liste modèle des médicaments essentiels

effacer Trouvé 36 recommandations pour 18 médicaments et 13 équivalents thérapeutiques
Les médicaments retirés et les demandes rejetées ne sont pas indiqués. Les afficher.
10. Medicines affecting the blood
  1. Acenocoumarol Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to warfarin pour Other specified diseases of arteries or arterioles Therapeutic equivalent to warfarin pour Venous thromboembolism Therapeutic equivalent to warfarin pour Cerebral ischaemic stroke due to embolic occlusion Therapeutic equivalent to warfarin pour Atrial fibrillation
  2. Apixaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  3. Dabigatran Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
    Indications
    Venous thromboembolism Other specified atrial fibrillation
  4. Dalteparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  5. Darbepoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  6. Deferasirox Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dispersible tablet: 100 mg; 125 mg; 250 mg; 400 mg; 500 mg
    • Oral > Solid > tablet: 90 mg; 180 mg; 360 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias Therapeutic equivalent to deferoxamine pour Thalassaemias
  7. Deferiprone Informations générales
    Section
    Other medicines for haemoglobinopathies
    Indications
    Therapeutic equivalent to deferasirox pour Other specified sickle cell disorders or other haemoglobinopathies Therapeutic equivalent to deferasirox pour Thalassaemias
  8. Deferoxamine Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies Thalassaemias
  9. Desmopressin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 150 µg per actuation (acetate)
    Indications
    Haemophilia A Von Willebrand disease
  10. Edoxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  11. Emicizumab Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 12 mg per 0.4 mL in vial; 30 mg per mL in mL vial; 60 mg per 0.4 mL in vial; 105 mg per 0.7 mL in vial; 150 mg per mL in vial; 300 mg per 2 mL in vial
    Indications
    Haemophilia A
  12. Enoxaparin Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule
    Indications
    Acute ischaemic heart disease Venous thromboembolism
  13. Epoetin alfa Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  14. Epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  15. Epoetin theta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  16. Erythropoiesis-stimulating agents Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
    Indications
    Anaemia due to chronic disease
  17. Ferrous salt Informations générales
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL elemental iron; 9 mg per mL elemental iron
    • Oral > Solid > tablet: 60 to 65 mg elemental iron
    Indications
    Iron deficiency anaemia
  18. Ferrous salt + folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid > tablet: 60 mg elemental iron + 400 µg tablet; 60 mg elemental iron + 2.8 mg
    Indications
    Clefts of lip, alveolus or palate Iron deficiency anaemia Anencephaly or similar anomalies Spina bifida
  19. Folic acid Informations générales
    Section
    Antianaemia medicines
    • Oral > Solid: 400 µg
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    Indications
    Anencephaly or similar anomalies Spina bifida Cephalocele Folate deficiency anaemia
  20. Heparin sodium Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 1 mL ampoule or vial; 20000 IU per mL in 1 mL ampoule or vial; 5000 IU per mL in 1 mL ampoule or vial
    Indications
    Acute ischaemic heart disease Unstable angina Venous thromboembolism
  21. Hydroxocobalamin Informations générales
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
    Indications
    Megaloblastic anaemia due to vitamin B12 deficiency
  22. Hydroxycarbamide (hydroxyurea) Informations générales
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg
    Indications
    Other specified sickle cell disorders or other haemoglobinopathies
  23. Methoxy polyethylene glycol-epoetin beta Informations générales
    Section
    Antianaemia medicines
    Indications
    Therapeutic equivalent to erythropoiesis-stimulating agents pour Anaemia due to chronic disease
  24. Nadroparin Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin pour Acute ischaemic heart disease Therapeutic equivalent to enoxaparin pour Venous thromboembolism
  25. Phytomenadione Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1 mg per 0.5 mL in ampoule; 10 mg per mL in ampoule; 1 mg per mL in ampoule; 2 mg per 0.2 mL in ampoule mixed micelle solution; 10 mg per mL in ampoule mixed micelle solution
    • Oral > Solid > tablet: 5 mg tablet
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors Haemorrhagic or haematological disorders of fetus or newborn
  26. Protamine sulfate Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in 5 mL ampoule or vial
    Indications
    Haemorrhagic disorder due to circulating anticoagulants or coagulation factors inhibitors
  27. Rivaroxaban Informations générales
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran pour Venous thromboembolism Therapeutic equivalent to dabigatran pour Other specified atrial fibrillation
  28. Tranexamic acid Informations générales
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Haemorrhage, not elsewhere classified
  29. Warfarin Informations générales
    Section
    Medicines affecting coagulation
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    • Oral > Solid > tablet: 5 mg (scored) (sodium); 1 mg (scored) (sodium); 2 mg (scored) (sodium); 0.5 mg (scored) (sodium); 3 mg (scored) (sodium)
    Indications
    Other specified diseases of arteries or arterioles Venous thromboembolism Cerebral ischaemic stroke due to embolic occlusion Atrial fibrillation